Tweet
I do not understand why you took so short reads...
Which command line did you use for fastx_trimmer?
Which command line did you use for fastx_trimmer?
-
-
I used "./fastx_trimmer -t 32 -i /home/inma/Escritorio/454reads.fasta", but I'm not sure if it's correct.Comment
-
Obviousély it is not!!
Why you do not use the command line I sent you last time?
This command line will extract the first 120nt of each read... (if you want the last 120nt, you can use your command line but with -t 120)
fastx_trimmer -f 1 -l 120 -i input -o output
Edena can not do miracles with 32nt_long reads.
I also already asked you but how many reads do you have (this point is crucial to know if it makes sens to use Edena...)
Cheers,
SylvainComment
-
Ok SylvainL.
I have 301453 reads (454 reads). I'm going to try this command line, Thank you!Comment
-
Do you have an estimation of your genome size?Comment
-
Which assembler are you using? It may be valuable to try multiple assemblers (for 454 data Celera, MIRA & Newbler are obvious ones to try) and compare the results.
Assembling with 32 nt reads might give you the most confident regions, but otherwise it's challenging to see that gaining you much. I would also caution that the different major error mode of 454 data (indels due to homopolymers) may confound a tool such as Edena. In general, it's hard to see how converting long reads to short reads is a gain; you are throwing out a lot of valuable information.Comment
-
Yes, I have. It's about 4,5 MbComment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment